首页> 外文期刊>Information & communications technology law >Analysis of TRIPS Agreement and the justification of international IP rights protection in the WTO's multilateral trading system, with particular reference to pharmaceutical patents
【24h】

Analysis of TRIPS Agreement and the justification of international IP rights protection in the WTO's multilateral trading system, with particular reference to pharmaceutical patents

机译:分析《与贸易有关的知识产权协议》和世贸组织多边贸易体系中国际知识产权保护的正当性,特别是涉及药品专利

获取原文
获取原文并翻译 | 示例
       

摘要

The entry of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement has seen the developing countries and the least developed countries (LDCs) suffer from the excessive burden of obligations imposed under the Agreement to embrace and implement a higher standard of intellectual property (IP) protection. One of the areas where the impact of the measures is most felt is on accessibility to affordable medicines for frontline treatment of diseases in developing countries and LDCs, where the majority of the HIV/AIDS sufferers come from. This inevitable plight, although well known, and posited by the developing countries and LDCs during the Uruguay round of negotiations, was overlooked. This also necessitated the Doha Deceleration, which does not seem to have addressed the problem. The developed countries have also successfully utilised the TRIPS Agreement's IP rights protection criteria as a benchmark, to develop a much higher IP rights protection agenda through the introduction of TRIPS-plus provisions in bilateral and other multilateral agreements entered into with developing countries. The winners in the game are the patent-holding pharmaceutical corporations, software corporations, media corporations, and the developed countries where they are incorporated. The ones at the receiving end are the developing countries and the LDCs who were promised technology transfer to build a modern economy by the developed countries, but are faced with multiple problems of non-availability of affordable medicines for health care, besides others. This article seeks to study the justification for an extended IP rights protection under the TRIPS Agreement through an analysis of the philosophical underpinnings of the IP rights and the patent regime. It will be argued that the TRIPS Agreement is a major obstacle that the developing countries and the LDCs have been made to face as Members of the WTO (World Trade Organisation), with no end in sight for their miseries, and that the only possible solution is a review or an amendment of the TRIPS Agreement.
机译:与贸易有关的知识产权协定(TRIPS)的加入使发展中国家和最不发达国家(LDC)遭受该协定规定的为接受和实施更高的知识产权标准而承担的过多负担。 (IP)保护。这些措施影响最大的领域之一是发展中国家和最不发达国家(这是大多数艾滋病毒/艾滋病患者来自的国家)获得可负担得起的药物用于一线治疗疾病的途径。这种不可避免的困境虽然众所周知,但在乌拉圭回合谈判中却被发展中国家和最不发达国家提出,却被忽略了。这也需要进行多哈减速,但似乎并未解决该问题。发达国家还成功地将《与贸易有关的知识产权协议》的知识产权保护标准作为基准,通过在与发展中国家签订的双边和其他多边协议中引入《与贸易有关的知识产权协议》规定,制定了更高的知识产权保护议程。游戏的获胜者是拥有专利的制药公司,软件公司,媒体公司以及注册它们的发达国家。接受方是发展中国家和最不发达国家,它们曾被发达国家承诺向其转让技术以建立现代经济,但除其他方面外,还面临着许多无法获得负担得起的保健药物的问题。本文旨在通过对IP权利和专利制度的哲学基础进行分析,研究根据TRIPS协议进行扩展IP权利保护的理由。有人认为,《与贸易有关的知识产权协议》是使发展中国家和最不发达国家成为世界贸易组织(世界贸易组织)成员所面临的主要障碍,而他们的痛苦并没有尽头,这是唯一可能的解决方案是对《 TRIPS协议》的审查或修正。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号